Literature DB >> 11414768

Genomic organization and isoform-specific tissue expression of human NAPOR (CUGBP2) as a candidate gene for familial arrhythmogenic right ventricular dysplasia.

D Li1, L L Bachinski, R Roberts.   

Abstract

Neuroblastoma apoptosis-related RNA-binding protein (NAPOR; HGMW-approved symbol CUGBP2) is a newly discovered gene prominently induced during apoptosis, suggesting that it plays a role during apoptosis. We have found that it is encoded by a gene located on chromosome 10p13-p14 between Généthon markers D10S547 and D10S223, a region to which we have recently localized a gene responsible for arrhythmogenic right ventricular dysplasia (ARVD). To examine its possible role in the pathogenesis of ARVD, we determined the genomic organization of the human NAPOR gene including its exon-intron boundaries and the putative promoter sequence, which provide a plausible mechanism for its alternative mRNA splicing. We also demonstrated that three isoforms of the NAPOR transcript were differently expressed, with NAPOR-3 being nearly neuron specific while the other two forms were ubiquitously expressed. The expression of NAPOR is differentially regulated during development. Finally, we screened the members of the ARVD family for mutations and identified two DNA sequence variants in the protein-coding exons of NAPOR, neither of which was responsible for ARVD. While the function of NAPOR remains to be elucidated, our current characterization of the NAPOR gene will be valuable for further clinical and functional study. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414768     DOI: 10.1006/geno.2001.6558

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  20 in total

Review 1.  Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a not so rare "disease of the desmosome" with multiple clinical presentations.

Authors:  Thomas Herren; Philipp A Gerber; Firat Duru
Journal:  Clin Res Cardiol       Date:  2009-02-09       Impact factor: 5.460

2.  Molecular biology of heart disease.

Authors:  Robert Roberts
Journal:  World J Cardiol       Date:  2011-04-26

3.  Identification of putative new splicing targets for ETR-3 using sequences identified by systematic evolution of ligands by exponential enrichment.

Authors:  Nuno André Faustino; Thomas A Cooper
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

Review 4.  The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins.

Authors:  Twishasri Dasgupta; Andrea N Ladd
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-08-17       Impact factor: 9.957

5.  Reduced Expression of RNA Binding Protein CELF2, a Putative Tumor Suppressor Gene in Colon Cancer.

Authors:  Satish Ramalingam; Prabhu Ramamoorthy; Dharmalingam Subramaniam; Shrikant Anant
Journal:  Immunogastroenterology       Date:  2012

6.  Region-specific alternative splicing in the nervous system: implications for regulation by the RNA-binding protein NAPOR.

Authors:  Wenqing Zhang; Haiying Liu; Kyoungha Han; Paula J Grabowski
Journal:  RNA       Date:  2002-05       Impact factor: 4.942

7.  Cardiac tissue-specific repression of CELF activity disrupts alternative splicing and causes cardiomyopathy.

Authors:  Andrea N Ladd; George Taffet; Craig Hartley; Debra L Kearney; Thomas A Cooper
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

8.  ETR-3 and CELF4 protein domains required for RNA binding and splicing activity in vivo.

Authors:  Gopal Singh; Nicolas Charlet-B; Jin Han; Thomas A Cooper
Journal:  Nucleic Acids Res       Date:  2004-02-18       Impact factor: 16.971

Review 9.  Posttranscriptional regulation of gene networks by GU-rich elements and CELF proteins.

Authors:  Irina A Vlasova; Paul R Bohjanen
Journal:  RNA Biol       Date:  2008-10-23       Impact factor: 4.652

10.  Diversity and conservation of CELF1 and CELF2 RNA and protein expression patterns during embryonic development.

Authors:  Y Blech-Hermoni; S J Stillwagon; A N Ladd
Journal:  Dev Dyn       Date:  2013-04-15       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.